Innovative nuclear medicine technologies, such as LINAC-based systems developed within the IFIGENEIA project, have the potential to significantly enhance diagnostic and therapeutic capabilities in healthcare. However, public understanding and acceptance are critical factors influencing the successful adoption of such technologies. PASYKAF contributes to IFIGENEIA by addressing the societal and ethical dimensions of nuclear medicine innovation, with a particular focus on building trust among patients and the wider public.
The term “nuclear medicine” can evoke uncertainty or concern, especially among patients already facing the emotional burden of a cancer diagnosis. Misconceptions about safety, radiation exposure, and long-term effects may create barriers to acceptance if not proactively addressed. Patient organisations play a key role in bridging this gap between scientific innovation and public understanding.
Through its involvement in IFIGENEIA, PASYKAF will support transparent, patient-oriented communication strategies that explain the benefits, safety measures, and purpose of LINAC-based technologies in an accessible language. Drawing on its extensive advocacy experience, PASYKAF highlights the importance of dialogue, education, and ethical sensitivity when introducing advanced medical infrastructures.
Civil society engagement strengthens innovation by ensuring that technological progress aligns with societal values and patient expectations. By involving patient organisations early in the innovation process, IFIGENEIA fosters a climate of openness and accountability, contributing to long-term sustainability and public confidence.
Integrating social perspectives alongside scientific excellence enables IFIGENEIA to advance nuclear medicine in a way that is not only effective, but also trusted, accepted, and supported by the communities it aims to serve